Print(PDF/132KB) May 18, 2017 R&D
Sumitomo Dainippon Pharma announces the Clinical Data will be presented at ASCO 2017
Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada) announced today that a total of 12 presentations including clinical data for investigational anti-cancer agents napabucasin (BBI608), amcasertib (BBI503) and WT2725 will be presented at the poster session of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from June 2 to June 6, 2017.
Napabucasin: Study results, 7 presentations
Abstract number | Title of poster presentation | Date and Time, Location | Study number | Cancer Type |
---|---|---|---|---|
9052 | A phase 1b/2 study of napabucasin with weekly paclitaxel in advanced, previously treated non-squamous non-small cell lung cancer. | June 3, 2017 8:00 AM-11:30 AM (local time), Hall A |
201 Study: NCT01325441 |
Non-small cell lung cancer |
3529 | Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts). | June 3, 2017 8:00 AM-11:30 AM (local time), Hall A |
246 Study: NCT02024607 |
Colorectal cancer |
4106 | A phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with gemcitabine (gem) and nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts). | June 3, 2017 8:00 AM-11:30 AM (local time), Hall A |
118 Study: NCT02231723 |
Pancreatic cancer |
5548 | A phase 1b/2 study of napabucasin with weekly paclitaxel in advanced, previously treated platinum resistant ovarian cancer. | June 3, 2017 1:15 PM-4:45 PM (local time) , Hall A |
201 Study: NCT01325441 |
Ovarian Cancer |
9553 | A phase Ib study of napabucasin plus weekly paclitaxel in patients with advanced melanoma. | June 3, 2017 1:15 PM-4:45 PM (local time) , Hall A |
201 Study: NCT01325441 |
Melanoma |
1084 | A phase 2 study of napabucasin with weekly paclitaxel in previously treated metastatic breast cancer. | June 4, 2017 8:00 AM-11:30 AM (local time) , Hall A |
201 Study: NCT01325441 |
Breast cancer |
4077 | BBI608-503-103HCC: A phase Ib/II clinical study of napabucasin (BBI608) in combination with sorafenib or amcasertib (BBI503) in combination with sorafenib (Sor) in adult patients with hepatocellular carcinoma (HCC). | June 3, 2017 8:00 AM-11:30 AM (local time) , Hall A |
BBI HCC 103 Study: NCT02279719 |
Hepato-cellular carcinoma |
Napabucasin: Study design, 2 presentations
Abstract number | Title of poster presentation | Date and Time, Location | Study number | Cancer Type | TPS3619 | CanStem303C trial: A phase III study of napabucasin (BBI-608) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC). | June 3, 2017 8:00 AM-11:30 AM (local time) , Hall A |
CanStem303C Study: NCT02753127 |
Colorectal cancer |
---|---|---|---|---|
TPS4148 | CanStem111P trial: A phase III study of napabucasin (BBI-608) plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC). | June 3, 2017 8:00 AM-11:30 AM (local time) , Hall A |
CanStem111P Study: NCT02993731 |
Pancreatic cancer |
Amcasertib: Study results, 2 presentations
Abstract number | Title of poster presentation | Date and Time, Location | Study number | Cancer Type | 6032 | A phase 1b/2 study of amcasertib, a first-in-class cancer stemness kinase inhibitor in advanced head and neck cancer. | June 5, 2017 1:15 PM-4:45 PM (local time) , Hall A |
101 Study: NCT01781455 |
Head and Neck cancer |
---|---|---|---|---|
6036 | A phase 1b/2 study of amcasertib, a first-in-class cancer stemness kinase inhibitor, in advanced adenoid cystic carcinoma. | June 5, 2017 1:15 PM-4:45 PM (local time), Hall A |
101 Study: NCT01781455 |
Adenoid Cystic Carcinoma |
WT2725: Study results, 1 presentation
Abstract number | Title of poster presentation | Date and Time, Location | Study number | Cancer Type | 2066 | Initial phase 1 study of WT2725 dosing emulsion in patients with advanced malignancies. | June 5, 2017 1:15 PM-4:45 PM (local time), Hall A |
D8350004Study :NCT01621542 |
Solid tumors, Hematologic malignancies |
---|
*The abstract is now available on the official website of ASCO. There is the link to applicable abstract on abstract number of each study.
(Reference)
【About napabucasin:BBI608】
Napabucasin is an investigational first-in-class anti-cancer agent created by Boston Biomedical, Inc., wholly-owned subsidiary of Sumitomo Dainippon Pharma. Napabucasin is an orally -administered small molecule agent with a novel mechanism of action designed to inhibit cancer stemness pathways by targeting STAT3.
【About amcasertib:BBI503】
Amcasertib is an investigational anti-cancer agent created by Boston Biomedical, Inc. Amcasertib is an orally-administered small molecule agent with a novel mechanism of action designed to inhibit cancer stemness pathways, including Nanog, by targeting stemness kinases.
【About WT2725】
WT2725 is an investigational therapeutic cancer peptide vaccine derived from Wilms' tumor gene 1 (WT1) protein. WT2725 is expected to treat various types of hematologic malignancies and solid tumors that express WT1, by inducing WT1-specific cytotoxic T-lymphocytes that attack WT1-expressing cancer cells.
Inquiries from the Press